HITHIUM
9.7.2024 12:43:27 CEST | Business Wire | Press release
Stationary battery manufacturer Hithium has successfully deployed the largest battery energy storage system (BESS) project in Eastern Europe to date, with a capacity of 55MWh. This solar plus storage project was realized completely by EPC company Solarpro, in Razlog, Southwestern Bulgaria, where the project is located.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709299471/en/
Hithium BESS project in Razlog, Bulgaria (Photo: Business Wire)
The new facility officially went live in early June, with the delivery of Hithium’s 16 energy storage containers, each with a capacity of 3.44MWh, to Solarpro. Solarpro is a leading technological provider of solutions for the generation and storage of energy within whole Europe.
Hithium ∞ Block 3.44MWh container
The Hithium ∞ Block 3.44MWh container is a liquid-cooled battery storage system based on Hithium prismatic LFP BESS cells with a 280Ah capacity and a high cyclic lifetime. It is specially optimized for use in stationary battery storage systems with high standards of safety, reliability, and performance. The system’s low levelized cost of storage (LCOS), combined with excellent thermal management, improves energy throughput by ensuring optimal operating temperature and high energy density. It also integrates with a thermal management system, fire protection system, battery management system (BMS), and more.
As Kelson Li, Hithium Senior Director of Sales of DACH, Northern & Eastern Europe said: "We are honored to partner with Solarpro. By providing comprehensive technical and after-sales support throughout the project lifecycle, we aim to foster local expertise and expand the network in Europe. We believe our collaboration with Solarpro will help to accelerate the renewable energy transition and make a positive impact in the region."
Krasen Mateev, CEO of Solarpro adds: "As strategic partners in this landmark project, we are excited to collaborate with Hithium in bringing this significant BESS utility to operation. This undertaking reflects Solarpro’s dedication to advance renewable energy infrastructure in Eastern Europe, ensuring a sustainable energy future for generations to come."
Hithium’s Commitment to the European Market
Hithium is committed to fostering a stronger and more collaborative relationship within the local European market. To this end, the company has set up a regional office in Munich, Germany, offering local support and services. Furthermore, Hithium has formed strategic alliances with other industry leaders, including Scan Global Logistics, to offer unparalleled transportation services, and CarbonX, to advance the energy sector in terms of environmental responsibility and technological advancement.
About Hithium
Hithium is a leading manufacturer of top-quality stationary energy storage products for utility-scale as well as commercial and industrial applications. With more than 20GWh BESS projects shipment up to date. Hithium took the top 5 global market shares and was ranked as the Tier 1 BESS supplier. With four distinct R&D centers and multiple “intelligent” production facilities, Hithium’s innovations include groundbreaking safety improvements to its lithium-ion batteries as well as increases in lifecycle. With decades of cumulative experience in the field among its founders and senior executives, Hithium leverages its specialization in BESS to deliver partners and customers unique advances in energy storage. The company is headquartered in Xiamen, China, with locations in Shenzhen, Chongqing, Munich, Dubai, New York and California.
About Solarpro
Solarpro is a multi-technology integrator with expertise in hybrid projects that include photovoltaic (PV), wind, battery energy storage systems (BESS), and hydrogen solutions. As a leading EPC contractor with 15 years of experience and a team of over 1,000 professionals, Solarpro has designed, built, and integrated PV plants with a total capacity exceeding 7 GW. The company is a technological innovator, excelling in engineering and digitalizing renewable projects, transforming them into dispatchable and flexible assets aligned with energy market developments. Committed to sustainability, Solarpro has further developed expertise in recycling PV modules and batteries to utilize damaged or polluted land, transforming them into state-of-the-art clean energy plants.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709299471/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom